Impact of Ageing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Impact of Ageing
Despite the fact that Europe's population is ageing rapidly, the region is astonishingly still underprepared for dealing with the health-related effect of this demographic trend. A major challenge for governments in the EU is meeting rising demand for healthcare whilst tailoring the systems to needs of the elderly.


Pharmaceutical Technology Europe
Volume 23, Issue 12

Inadequate representation of the elderly in clinical trials

While the elderly account for high drug consumption, they remain underrepresented in clinical trials. A number of European geriatricians have gone as far as to launch a charter against ageism in clinical trials, highlighting that practical issues in involving elderly people in clinical trials are not the only reason for such observations. These views are the result of their involvement in the European-wide PREDICT consortium for "Increasing the Participation of the Elderly In Clinical Trials" (6). Coordinated from the Medical Economics & Research Centre, Sheffield, UK, the PREDICT initiative began in February 2008 and has received support from the EU and FP7 Health research (the Seventh Framework Programme of the EU for the funding of research and technological development in Europe). The aim of PREDICT is to investigate reasons for the exclusion of the elderly in clinical trials and to provide solutions for this problem. Those behind PREDICT highlight that an analogous problem occurred in the paediatric population, but research in this domain has considerably improved and therefore offers an example of what can be achieved.

Several key European geriatricians state that they have often found themselves in a situation where they were unable to offer patients the best course of treatment with the weight of scientific evidence behind them because of insufficient evidence from clinical trials (6). The group has also carried out extensive reviews of medical literature for conditions prevalent in elderly people to back their opinions. In 2010, PREDICT researchers reported findings from interviews with health professionals in nine countries, as well as from more than 50 focus groups with elderly people and their carers. More recently, it published some of its conclusions in a peer-reviewed paper in the Archives of Internal Medicine, focusing primarily on the extent of exclusion of older individuals in ongoing clinical trials regarding heart failure (7).

The EMA has also taken account of the demographic implications of ageing. In October 2011, it issued an invitation for expressions of interest in an EMA workshop on medicines for older people (8). The provisional dates stated for the workshop are March 22–23, 2012. The workshop will feature a presentation and discussion of the EMA geriatric medicines strategy and related activities, so that gaps in the strategy can be identified. The EMA hopes that a presentation of its strategy in this field will provide opportunity for the identification of synergy areas between stakeholders. It will also seek input on the regulatory mechanisms it is developing to boost geriatric medicine. The sessions currently planned focus on themes that match the EC's European Year of Active Ageing initiative, namely healthy ageing and medicines, demonstrating safety and efficacy in the older population, geriatric pharmacovigilance, and the role of regulatory agencies in providing information to the older population.

Opportunities for the pharmaceutical industry

For the pharmaceutical industry, a renewed focus on the elderly population offers a tremendous research and commercial opportunity. The work of the PREDICT group and the EMA should also help companies to trial their drugs in this underserved section of the population.

It is predicted that the Alzheimer's disease drug market will nearly triple over the next 10 years, increasing from €4 billion in 2010 to €10.6 billion in 2020 in the major markets of the US, France, Germany, Italy, Spain, the UK and Japan (9). At present the market is dominated by symptomatic therapies that only provide modest effects on cognitive and functional decline but there is a need for more effective drugs. To date, governments have been unwilling to fund expensive new therapies. For example, the UK's National Institute for Clinical Excellence (NICE) caused considerable patient anger in 2007 when it ruled that Aricept and similar drugs should be restricted to people whose dementia had progressed from mild to the moderate, but has not yet reached severe (10). The pharmaceutical industry must find natural allies among patient organisations and clinicians who are dissatisfied with the availability of treatments for elderly section of the population. If governments have publicly stated that they will back initiatives to improve healthcare for the elderly, then their commitment to reimbursing new therapies will be expected.

Companies are aware that pricing will remain important and in the US market, which is becoming more cost conscious, many firms are attempting to become more proactive. For example, Pfizer recently signed a five-year agreement with the US healthcare insurer Humana to investigate treatment costs for the elderly in chronic pain, cardiovascular disease and Alzheimer's disease. The two companies will look at products in relation to healthcare resources and reducing costs (11). The Pharmaceutical Research and Manufacturers of America (PhRMA) industry body has highlighted the cost of failing to treat chronic diseases, estimated it to be as much as 75 cents of every dollar spent on healthcare in the US (12).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology Europe,
Click here